Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

Dr. Sean McWilliams brings two decades of specialized ear, nose and throat expertise to Mid Bay ENT, offering expanded ...

Chronic inflammation refers to a prolonged inflammatory response that involves a progressive change in the type of cells present at the site of inflammation. It is characterized by the ...

Patients with CRSwNP have a high burden of SCS use and associated health care costs, especially when they have comorbid asthma.

Comorbid asthma, nonsmoking status, and the ethmoid/maxillary sinus ratio were significant predictors of eosinophilic CRSwNP.

Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks.

Last year, Priyanka Chopra opened up about a cosmetic procedure she deeply regrets. During an interview on Howard Stern’s ...

Discover how asthma contributes to bronchiectasis development through sinusitis and inflammation. Learn about new findings ...